TOLREMO therapeutics
Latest round
- Series A
Last raised
- Sep 2023
Total raised
- $53M
Investors
- 5
About TOLREMO therapeutics
Founded in 2017 and headquartered in Muttenz, Switzerland, TOLREMO therapeutics AG develops breakthrough cancer therapies. The company was founded by Stefanie Flückiger-Mangual, who has a history of entrepreneurship in the biotech sector.TOLREMO therapeutics specializes in developing innovative cancer therapies, focusing on addressing non-oncogene addiction through the inhibition of transcriptional escape pathways. Their primary product is TT125-802, an orally available small molecule inhibitor targeting the bromodomain of the epigenetic regulators CBP/p300. This compound aims to disrupt transcriptional resistance mechanisms that can lead to drug resistance in cancer treatments. Positioned as a best-in-class option for treating solid tumors and hematological malignancies, TT125-802 intends to enhance patient outcomes both as a monotherapy and in combination with existing targeted therapies.TOLREMO therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions focused on cancer treatment. The company engages in direct B2B transactions, providing clinical compounds like TT125-802 to clinical trial partners and larger oncology-focused entities for further development and commercialization. The company plans to introduce new products designed to further enhance treatment options for cancer patients, with upcoming launches aimed at expanding its therapeutic portfolio. Additionally, TOLREMO aims to grow its presence in new markets, particularly targeting expansion in North America and other European regions by 2025.
Who invested in TOLREMO therapeutics
5 investors across 3 rounds
See all investors in TOLREMO therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about TOLREMO therapeutics
Who invested in TOLREMO therapeutics?
TOLREMO therapeutics has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TOLREMO therapeutics raised?
TOLREMO therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did TOLREMO therapeutics last raise money?
TOLREMO therapeutics's most recent round on record is a Series A, in Sep 2023.
What does TOLREMO therapeutics do?
Founded in 2017 and headquartered in Muttenz, Switzerland, TOLREMO therapeutics AG develops breakthrough cancer therapies.
Where is TOLREMO therapeutics headquartered?
TOLREMO therapeutics is headquartered in Muttenz, Switzerland.
Which VCs invest in companies like TOLREMO therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at TOLREMO therapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like TOLREMO therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.